Valentine N. Ndikum

Valentine N. Ndikum

Auto-generated profile, based on publicly available information

Valentine N. Ndikum

Laboratory for Public Health Research Biotechnologies, University of Yaoundé I, BP 8094, Yaoundé, Cameroon

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ANAkindeh Mbuh Nji
Akindeh Mbuh Nji
IAInnocent Ali
Innocent Ali
MMMarcel N Moyeh
Marcel N Moyeh
ENEric-Oliver Ngongang
Eric-Oliver Ngongang
AMARISTID Mbange
ARISTID Mbange
WMWilfred Fon Mbacham
Wilfred Fon Mbacham
Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological regions of Cameroon. A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1, respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up. The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5% confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was accepted if the lower limit of the CI was greater than −10%. Secondary outcomes were parasite and fever clearances and day 7 haemoglobin changes. PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in AL and ASAQ groups, AL and DHAP groups were, −6% and −4% respectively. There were no statistical significant differences in parasite or fever clearance times between treatments, although fever clearance pattern was different between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events among treatment groups. ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children. NCT01845701

2 May 2018 in Malaria Research and Treatment
Verified
Journal Article
Open access
PDF file
MMMarcel N. Moyeh
Marcel N. Moyeh
DNDieudonne L. Njimoh
Dieudonne L. Njimoh
MEMarie Solange Evehe
Marie Solange Evehe
IAInnocent Ali
Innocent Ali
ANAkindeh M. Nji
Akindeh M. Nji
WMWilfred Fon Mbacham
Wilfred Fon Mbacham
Background. As a result of the spread of parasites resistant to antimalarial drugs, Malaria treatment guidelines in Cameroon evolved from nonartemisinin monotherapy to artemisinin-based combination therapy. The aim of this study was to assess the effect of these therapy changes on the prevalence of molecular markers of resistance from 2003 to 2013 in Mutengene, Cameroon. Methodology. Dry blood samples (collected in 2003–2005 and 2009–2013) were used for parasite DNA extraction. Drug resistance genes were amplified by PCR and hybridized with oligonucleotide probes or subjected to restriction digestion. The prevalence of individual marker polymorphisms and haplotypes was compared in these two study periods using the Chi square test. Results. Alleles conferring resistance to 4-aminoquinolines in the Pfcrt 76T and Pfmdr1 86Y, 184F, and 1246Y genotypes showed a significant reduction of 97.0% to 66.9%, 83.6% to 45.2%, 97.3% to 56.0%, and 3.1% to 0.0%, respectively (P<0.05). No difference was observed in SNPs associated with antifolate drugs resistance 51I, 59R, 108N, or 540E (P>0.05). Haplotype analysis in the Pfmdr1 gene showed a reduction in the YFD from 75.90% to 42.2%, P<0.0001, and an increase in the NYD (2.9% to 30.1%; P<0.0001). Conclusions. The results indicated a gradual return of the 4-aminoquinoline sensitive genotype while the antifolate resistant genotypes increased to saturation.

1 September 2001 in Pathogens and Global Health
Verified
Journal Article
Closed access
ASA. Sowunmi
A. Sowunmi
AAA. I. Ayede
A. I. Ayede
AFA. G. Falade
A. G. Falade
VNV. N. Ndikum
V. N. Ndikum
CSC. O. Sowunmi
C. O. Sowunmi
AOA. M. J. Oduola
A. M. J. Oduola
The increasing resistance of Plasmodium falciparum to chloroquine (CQ) has created an urgent need for the evaluation of alternative, effective, safe, cheap, readily available and affordable antimalarial treatments. In the present study, the efficacy of amodiaquine (AQ) in the treatment of acute, symptomatic, uncomplicated, P. falciparum malaria was compared with that of CQ, each drug being given at 10 mg/kg per day for 3 days (days 0, 1 and 2). The 210 subjects (104 given AQ and 106 CQ) were Nigerian children aged 5 months-12 years. Fever-clearance times (FCT), parasite densities on days 1-4 and parasite-clearance times (PCT) were all significantly lower with AQ than with CQ. Mean (S.D.) PCT, for example, were 2.6 (0.8) days with AQ and 3.0 (1.0) days with CQ (P = 0.001). The cure rates obtained on days 14, 21 and 28 - 98.1% v. 79.3% (P =0.000), 97.1% v. 64.2% (P = 0.00001) and 95.2% v. 58.5% (P = 0.0000000) with AQ and CQ, respectively - were all also significantly higher with AQ. All but two of the 20 subjects who were considered CQ-treatment failures by day 14 (i.e. two RIII, two RII and 16 RI) responded to subsequent treatment with AQ, with PCT (but not FCT) significantly shorter than during their initial treatment with CQ. In siblings in whom there was clustering of infections, the cure rates were 100% with AQ (N =12) and 63.6% with CQ (N = 11; P = 0.03). Adverse reactions to CQ and AQ were similar and tolerable: pruritus in 10 and 11 children in the AQ and CQ groups, respectively, and gastro-intestinal disturbances which occurred in three children from each group. Haematological parameters were not adversely affected by either drug. At least in the setting of the present study, AQ appears more effective than CQ, effective against CQ-resistant infections, and well tolerated by children with acute, uncomplicated, P. falciparum malaria. It may therefore be useful as an alternative to CQ in areas of CQ resistance.

31 October 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
DMDaniel Ethe Maka
Daniel Ethe Maka
ACAndreas Chiabi
Andreas Chiabi
VNValentine Ndikum
Valentine Ndikum
DADorothy Achu
Dorothy Achu
EMEvelyn Mah
Evelyn Mah
EMElie Mbonda
Elie Mbonda
Severe malaria is a medical emergency with high mortality in children below 5 years of age especially in sub-Saharan Africa. Recently, quinine has been replaced by artesunate as the first-line drug in the treatment of severe malaria in Cameroon. No local data are yet available on the efficacy of artesunate with respect to the different quinine regimens used in this setting. This study was undertaken at the Ebolowa Regional Hospital (ERH), which is located in a region of perennial transmission of malaria. This was a randomized, open-label trial in children aged 3 months to 15 years, admitted in the hospital with severe malaria due to Plasmodium falciparum confirmed on microscopy after informed parental consent. Patients were randomized into four groups. Group 1 (ARTES) received parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily; Group 2 (QLD) received a loading dose of quinine base at 16.6 mg/kg followed 8 hours later by an eight-hourly maintenance dose of 8.3 mg/kg quinine base; Group 3 (QNLD3) received 8.3 mg/kg quinine base every 8 hours; and, Group 4 (QNLD2) received 12.5 mg/kg quinine base every 12 h. All patients invariably received a minimum of 24 h parenteral treatment, then, oral drugs were prescribed. The endpoints were fever clearance time, time to sit unsupported, time to eat, parasite clearance time, and parasitaemia reduction rate at H24. Survival analysis was used to compare the outcomes. One-hundred and sixteen patients completed the study: 29 in ARTES arm, 28 in QLD arm, 30 in QNLD3 arm, and 29 in QNLD2 arm. There was no major differences in baseline characteristics in the treatment groups. On analysis of endpoints, fever clearance time and parasite clearance time were significantly shorter for artesunate-treated patients than for quinine-treated patients. Parasitaemia reduction rate at H24 was also significantly higher for artesunate. Time to sit unsupported and time to eat were shorter with artesunate, but the difference was not statistically significant. Artesunate is more effective than quinine in the treatment of severe malaria in Cameroonian children.

30 November 2012 in Journal of Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
FCFokunang C.N.
Fokunang C.N.
MNMejane N.N.
Mejane N.N.
NENoumie E.
Noumie E.
NBNgameni B.
Ngameni B.
GHGonsu H.K.
Gonsu H.K.
NBNgadjui B.T.
Ngadjui B.T.
Bacterial resistance to classical antibiotics nowadays is becoming a health concern in Cameroon. Patients suffering from bacteria attack spend money to carry out laboratory tests for effective diagnosis, with very little positive results. This is due to the fact that most of our hospitals lack the up to date laboratory equipments, to detect the real antibiotic that will kill a particular bacterium. This has led to more patients spending a lot of money on bacterial infection treatment, and some even end up dying with the disease. It is on this basis that this work was designed to research the antibacterial properties of the extracts namely crude extract, hexane-acetate 25%, hexane-acetate 50%, hexane-acetate 75%, hexane, acetate and methanol of the leaves of Dorstenia mannii, a plant that is readily available from our natural environment at little or no cost. These extracts were tested on the following bacteria species namely; Gram-negative bacteria; Enterobacter aerogenes, Escherichia coli, Klebsiella sp., Proteus mirabilis, Pseudomonas aeruginosa, Salmonella enterica; Gram-positive bacteria; Staphylococcus aureus and Bacillus sp. After some laboratory analysis using the antibiogramme sensitivity test, it was discovered that the extracts of the leaves of D. mannii were only sensitive on three of the eight bacteria used which were, E. coli, S. enterica and Klebsiella sp. The other five namely; P. aeruginosa, E. aerogenes, P. mirabilis, S. aureus and Bacillus sp, were resistant to the extract. The sensitivity level of the three bacteria, that showed positive response where however low. Therefore, more research has to be carried out using different concentrations of the leaves extract for a more conclusive result. This concentration could permit to appreciate the degree of sensitivity and also to see if other bacteria that have not manifested any sensitivity can show some positive response to the extracts. Also, different laboratory methods and more bacteria should be used to prove that the leaves of D. mannii have the potential as a promising antibacterial medicinal plant to either render bacteria inactive or kill them completely. Key words: Antibacterial properties, Dorstenia mannii, strain sensitivity, gram positive, gram negative bacteria